|1.||Grant, Steven: 54 articles (05/2015 - 01/2002)|
|2.||Dent, Paul: 51 articles (09/2015 - 01/2002)|
|3.||Druker, Brian J: 48 articles (12/2015 - 03/2002)|
|4.||Gray, Nathanael S: 47 articles (09/2015 - 12/2007)|
|5.||Heinrich, Michael C: 47 articles (03/2015 - 03/2002)|
|6.||Salgia, Ravi: 45 articles (06/2015 - 01/2003)|
|7.||Lang, Florian: 42 articles (09/2015 - 01/2002)|
|8.||Zhang, Wei: 42 articles (08/2015 - 11/2002)|
|9.||Alessi, Dario R: 42 articles (08/2015 - 12/2002)|
|10.||Rosen, Neal: 37 articles (12/2015 - 06/2002)|
12/01/2015 - "Targeted kinase inhibitors have dramatically improved cancer treatment, but kinase dependency for an individual patient or cancer cell can be challenging to predict. "
09/08/2015 - "Novel targeted cancer therapies, especially kinase inhibitors, have revolutionized the treatment of many cancers and have dramatically improved the survival of several types of malignancies. "
07/25/2013 - "Mutations in the catalytic domain at the gatekeeper position represent the most prominent drug-resistant variants of kinases and significantly impair the efficacy of targeted cancer therapies. "
01/01/2013 - "QSAR predictions have been proven very useful in a large number of studies for drug design, such as kinase inhibitor design as targets for cancer therapy, however the overall predictability often remains unsatisfactory. "
01/01/2012 - "Among the many inhibitors available for this kinase, the recently developed CX-4945 and CX-5011 have proved to be very potent, selective and effective in inducing cell death in tumor cells; CX-4945 has recently entered clinical trials. "
|2.||Melanoma (Melanoma, Malignant)
03/01/2015 - "Following the discovery that nearly half of all cutaneous melanomas harbour a mutation in the BRAF gene, molecular targeted kinase inhibitors have been developed for the treatment of metastatic melanoma and have dramatically improved outcomes for those patients with BRAF mutant disease, achieving high levels of objective response and prolonging survival. "
07/01/2012 - "Aberrant activation of the BRAF kinase occurs in ∼60% of melanomas, and although BRAF inhibitors have shown significant early clinical success, acquired resistance occurs in most patients. "
06/01/2015 - "Vemurafenib is a BRAF kinase inhibitor which has demonstrated significant improvement in disease-specific survival in patients with metastatic melanoma with a BRAF gene mutation. "
08/21/2014 - "Notably, PDKi was as effective in inhibiting AGC kinases and colony forming efficiency of melanoma with Pten wild-type (WT) genotypes. "
06/01/2014 - "A combined inhibition strategy targeting BRAF together with multiple erbB family kinases is potentially beneficial for treating BRAF V600E mutant melanoma. "
|3.||Breast Neoplasms (Breast Cancer)
07/01/2002 - "In this study, we explored the efficacy of a type 5 recombinant adenovirus encoding a kinase dead form of ErbB-2, AderbB-2 Delta tk, as a potential therapeutic agent for breast cancer using a murine breast model expressing constitutively active ErbB-2. "
11/15/2010 - "However, they also indicate that patient stratification based on expression/activation of drug targets, coupled with use of multi-kinase inhibitors or combination therapies, may be required for effective treatment of this breast cancer subgroup."
03/01/2013 - "In the present study, in order to optimize the efficacy of replication-defective adenoviral and lentiviral vectors for gene therapy, RT-PCR was used to evaluate the expression of Drosophila melanogaster deoxyribonucleoside kinase (Dm-dNK) in the Bcap37 human breast cancer cell line, dThd was used to determine the activity of Dm-dNK, cell cytotoxicity was evaluated by MTT assay and cell proliferation was assessed using a hemocytometer. "
08/01/2012 - "The aim of this study was to evaluate the selective killing efficacy of adenovirus (Ad)-mediated double suicide genes driven by the kinase domain-containing receptor (KDR) promoter in human breast cancer cells and vascular endothelial cells. "
01/01/2007 - "All of these concepts are being revisited with respect to the efficacy of HER family TKI therapies; in particular, HER3 signalling buffered against incomplete inhibition of HER2 kinase activity has been suggested to be the mechanism that allows HER2 over-expressing breast cancer cells to escape HER TKIs. "
|4.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
09/01/2010 - "Inhibition of BCR-ABL with kinase inhibitors in the treatment of Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML) is highly effective in controlling but not curing the disease. "
09/01/2010 - "Inhibition of BCR-ABL with kinase inhibitors has become a well-accepted strategy for targeted therapy of Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML) and has been shown to be highly effective in controlling the disease. "
02/01/2011 - "Chronic myeloid leukemia therapy has remarkably improved with the use of frontline BCR-ABL kinase inhibitors such that newly diagnosed patients have minimal disease manifestations or progression. "
10/01/2007 - "Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia."
01/01/2005 - "[Cytogenetic response as a marker of efficacy of chronic myeloid leukemia therapy with a BCR-ABL thyrosine kinase inhibitor glivek]."
09/01/2013 - "Recent studies have demonstrated that volatile anesthetic postconditioning confers myocardial protection against ischemia-reperfusion injury through activation of the reperfusion injury salvage kinase (RISK) pathway. "
02/24/2012 - "Extracellular-regulated-kinase 5-mediated renal protection against ischemia-reperfusion injury."
01/01/2016 - "Growing evidence from basic and clinical studies demonstrates that a DPP-4 inhibitor could exert cardioprotection and improve left ventricular function by reducing oxidative stress, apoptosis, and increasing reperfusion injury salvage kinase (RISK) activity. "
07/05/2015 - "In this study, we investigated whether cardioprotection induced by NP202 depended on activation of the reperfusion injury survival kinase (RISK) pathways. "
02/27/2015 - "In this study, we investigated the roles of reperfusion injury salvage kinase (RISK) and apoptosis-related pathways in the attenuation of cardioprotection of IPoC in the presence of HC. "
|1.||tyrosine receptor (receptor, tyrosine)
|5.||Protein Kinases (Protein Kinase)
|6.||sorafenib (BAY 43-9006)
|8.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)
|4.||Molecular Targeted Therapy